|
Home /
Novo Nordisk
Novo Nordisk Pharmaceutical
 Novo Nordisk
Pharmaceutical
As a world leading healthcare /
pharmaceutical company, Novo Nordisk has aleading position in diabetes care,
haemostasis management, growth hormone therapy and hormone replacement therapy.
Novo Nordisk has headquarters in Denmark, employs approximately 26,000
employees, operates in 79 countries and markets its products in 180
countries.
The Novo Nordisk Foundation
The Novo Nordisk Foundation is a non-profit
institution. Novo A/S is an unlisted Danish public limited liability company,
owned by the Novo Nordisk Foundation and established to manage the Foundation's
funds and to invest actively in other healthcare and pharmaceutical companies.
Novo Nordisk was created in 1989 through a merger between Novo Industri A/S and
Nordisk Gentofte A/S.
Novo Nordisk - research & development
As a focused healthcare company, Novo
Nordisk has a world class reputation in research & development, along with
equally world-class protein expertise. Novo Nordisk has pioneered diabetes
research and therapeutic development for more than 80 years and throughout
these years, Novo Nordisk has refined their protein expertise, sustaining it at
world-class level.
Latest Novo Nordisk news
Novo Nordisk further information:
www.novonordisk.com /
www.novonordisk.co.uk/ /
Novo Nordisk news
Page last updated:
09/06/08 |
